Table 1 Baseline characteristics of included studies
Author, Year | Data set | N(M/F) | Site, Stage | Chemotherapy | Endpoint | SQa |
|---|---|---|---|---|---|---|
Chau, 2005 [15] | Multicenter, UK | 801(431/370) | CRC, stage II/III | 5FU/LV, 5FU (continuous) | OS | 4 |
Andre, 2007 [16] | Multicenter, France | 905 (489/416) | Colon, stage II/III | LV/5FU2, FU + LV | OS,DFS | 4 |
Berglund, 2008 [17] | Norway and Denmark | 231(125/106) | Colon, stage III | / | OS | 5 |
Owens, 2009 [19] | MCR, US | 3006(1363/1643) | Colon, stage II/III | / | OS | 6 |
Cheung, 2009 [18] | SEER-Medicare, US | 6059(3147/2912) | Rectum, stage II/III | / | OS,DFS | 5 |
Ahmed, 2010 [20] | Multicenter,Canada | 663 (387/276) | Colon, III, Rectal II, III | 5FU based | OS,DFS | 7 |
Bayraktar, 2011 [21] | Multicenter,US | 186(72/114) | Colon, stage II/III | 5FU based | OS,RFS | 8 |
Czaykowski, 2011 [22] | Multicenter,Canada | 345(181/164) | Colon, stage III | 5FU/LV | OS,RFS | 7 |
Lima, 2011 [23] | ACR,Canada | 1053 (545/508) | Colon, stage III | 5FU based | OS | 5 |
Kang, 2013 [24] | Korea | 159 (73/86) | CRC, stage III | 5FU based | OS,RFS | 6 |
Tevis, 2013 [25] | UWHC, US | 355(206/149) | Rectum, stage I-IV | / | OS, LR | 7 |
Yu, 2013 [26] | US | 102(45/57) | Colon, stage III | FOLFOX/Xeloda | RFS | 5 |
Day, 2013 [27] | UK | 209(118/91) | CRC, Duke A-C | / | OS | 7 |
Tsai, 2013 [40] | Taiwan | 1054 (528/526) | CRC, stage III | 5-FU-based | OS, CSS | 6 |
Xu, 2014 [28] | SEER-Medicare, US | 4209(1954/2225) | Colon, stage II | / | OS, CSS | 5 |
Bos, 2015 [29] | NCR, Netherlands | 6620(3530/3090) | Colon, stage III | / | OS | 6 |
Jeong, 2015 [30] | Korea | 424(246/178) | Colon, stage II/III | FOLFOX4/FL | DFS | 8 |
Jeong, 2015 [31] | Korea | 133(62/71) | Colon, stage III | 5FU based | OS,DFS | 7 |
Kim, 2015 [32] | Korea | 750(475/275) | CRC, stage II/III | 5FU based | OS,RFS | 6 |
Klein, 2015 [33] | DCCG, Denmark | 1827(952/875) | Colon, stage III | NR | OS | 4 |
Nachiappan, 2015 [34] | HES, UK | 18,306(9889/8417) | Colon, NR | NR | OS | 7 |
Peixoto, 2015 [35] | BCCA, Canada | 635(329/306) | Colon, stage III | Oxa-based | RFS, CSS | 7 |
Santos, 2016 [12] | Multicenter, Brazil | 1306(643/663) | CRC, stage II/III | NR | OS,DFS | 7 |
Sun, 2016 [9] | NCDB, US | 7794(3722/4072) | Colon, stage II/III | NR | OS | 6 |
Kim, 2017 [36] | Multicenter, Korea | 5535(3187/2348) | Colon, stage II/III | 5FU/Oxa-based | OS | 7 |
Becerra, 2017 [39] | NYSCR, US | 1133 (498/635) | Colon, stage III | NR | CSS, OS | 7 |
Gao, 2018 [10] | SEER-Medicare, US | 9722(NR) | Colon, stage III | 5FU based | OS | 4 |
Turner, 2018 [11] | NCDB, US | 51,250 (25,275/25975) | Colon, stage III | NR | OS | 5 |
Choi, 2022 [37] | HIRA, Korea | 45,592 (27,148/18444) | CRC, stage II/III | 5FU based | OS | 6 |
Farzaneh, 2023 [38] | NCDB, US | 8722 (5012/3710) | Rectum, stage II/III | NR | OS | 6 |